Compare MEDP & NCLH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEDP | NCLH |
|---|---|---|
| Founded | 1992 | 1966 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9B | 10.9B |
| IPO Year | 2016 | 2011 |
| Metric | MEDP | NCLH |
|---|---|---|
| Price | $470.28 | $19.80 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 17 |
| Target Price | ★ $498.25 | $26.00 |
| AVG Volume (30 Days) | 274.5K | ★ 20.4M |
| Earning Date | 04-22-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.98 | N/A |
| EPS | ★ 15.28 | 0.92 |
| Revenue | N/A | ★ $5,396,175,000.00 |
| Revenue This Year | $13.15 | $10.08 |
| Revenue Next Year | $7.47 | $6.60 |
| P/E Ratio | $30.50 | ★ $22.00 |
| Revenue Growth | N/A | ★ 10.71 |
| 52 Week Low | $250.05 | $14.21 |
| 52 Week High | $628.92 | $27.18 |
| Indicator | MEDP | NCLH |
|---|---|---|
| Relative Strength Index (RSI) | 49.11 | 43.91 |
| Support Level | $452.55 | $17.67 |
| Resistance Level | $477.04 | $20.15 |
| Average True Range (ATR) | 15.21 | 0.85 |
| MACD | 4.12 | 0.04 |
| Stochastic Oscillator | 61.13 | 46.15 |
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 71,000). It operates 34 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 13 passenger vessels on order among its brands through 2036, representing 38,400 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.